TISIDB

Summary
Symbol	TDRD5
Name	tudor domain containing 5
Aliases	FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Note=Localizes to chromatoid body (CB) and pi-body (also called intermitochondrial cementin), 2 cytoplasmic ribonucleoprotein granules involved in RNA processing for spermatogenesis.
Domain	PF12872 OST-HTH/LOTUS domain PF00567 Tudor domain
Function	Required during spermiogenesis to participate in the repression transposable elements and prevent their mobilization, which is essential for the germline integrity. Probably acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and govern the methylation and subsequent repression of transposons. Required for chromatoid body (CB) assembly (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0000578 embryonic axis specification GO:0003002 regionalization GO:0006304 DNA modification GO:0006305 DNA alkylation GO:0006306 DNA methylation GO:0007028 cytoplasm organization GO:0007281 germ cell development GO:0007283 spermatogenesis GO:0007286 spermatid development GO:0007292 female gamete generation GO:0007308 oocyte construction GO:0007309 oocyte axis specification GO:0007314 oocyte anterior/posterior axis specification GO:0007315 pole plasm assembly GO:0007350 blastoderm segmentation GO:0007351 tripartite regional subdivision GO:0007389 pattern specification process GO:0008358 maternal determination of anterior/posterior axis, embryo GO:0008595 anterior/posterior axis specification, embryo GO:0009798 axis specification GO:0009880 embryonic pattern specification GO:0009948 anterior/posterior axis specification GO:0009952 anterior/posterior pattern specification GO:0009994 oocyte differentiation GO:0021700 developmental maturation GO:0022412 cellular process involved in reproduction in multicellular organism GO:0030719 P granule organization GO:0032259 methylation GO:0035282 segmentation GO:0043046 DNA methylation involved in gamete generation GO:0043414 macromolecule methylation GO:0044728 DNA methylation or demethylation GO:0048232 male gamete generation GO:0048469 cell maturation GO:0048477 oogenesis GO:0048515 spermatid differentiation GO:0048599 oocyte development GO:0071826 ribonucleoprotein complex subunit organization
Molecular Function	-
Cellular Component	GO:0033391 chromatoid body GO:0035770 ribonucleoprotein granule GO:0036464 cytoplasmic ribonucleoprotein granule GO:0043186 P granule GO:0045495 pole plasm GO:0060293 germ plasm GO:0071546 pi-body

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	TDRD5
Name	tudor domain containing 5
Aliases	FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TDRD5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	TDRD5
Name	tudor domain containing 5
Aliases	FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TDRD5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TDRD5
Name	tudor domain containing 5
Aliases	FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TDRD5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.126	0.8
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.084	0.948
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.186	0.914
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.416	0.626
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.198	0.433
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-1.964	0.298
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.47	0.487
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.991	0.275
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.808	0.0267

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TDRD5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	0	14.3	0.196
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	20	0	20	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	8.2	6.6	0.452
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	10.2	4.6	0.718
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	23.8	17.6	6.2	0.709
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	30.8	27.3	3.5	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	13.2	7.4	5.8	0.69
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	7.7	5.9	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	12.5	7.1	5.4	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	TDRD5
Name	tudor domain containing 5
Aliases	FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TDRD5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TDRD5
Name	tudor domain containing 5
Aliases	FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TDRD5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TDRD5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TDRD5
Name	tudor domain containing 5
Aliases	FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TDRD5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TDRD5
Name	tudor domain containing 5
Aliases	FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TDRD5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TDRD5
Name	tudor domain containing 5
Aliases	FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TDRD5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TDRD5
Name	tudor domain containing 5
Aliases	FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TDRD5 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse TDRD5